Evidence map›Paper›PMID 33608849›Full record

ArticleAnnals of hematology2021

Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.

S Bernard, L Hachon, J F Diasonama, C Madaoui, L Aguinaga, E Miekoutima, H Moatti, Emeline Perrial, I Madelaine, P Brice and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Evaluation of an oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

S BernardService d'hémato-Oncologie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), 1, Avenue Claude Vellefaux, 75010, Paris, France.
L HachonService de Pharmacie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), F-75010, Paris, France.
J F DiasonamaService d'hémato-Oncologie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), 1, Avenue Claude Vellefaux, 75010, Paris, France.
C MadaouiService de Pharmacie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), F-75010, Paris, France.
L AguinagaService d'hémato-Oncologie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), 1, Avenue Claude Vellefaux, 75010, Paris, France.
E MiekoutimaService d'hémato-Oncologie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), 1, Avenue Claude Vellefaux, 75010, Paris, France.
H MoattiService d'hémato-Oncologie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), 1, Avenue Claude Vellefaux, 75010, Paris, France.
Emeline PerrialINSERM 1052/CNRS 5286, F-69003, Lyon, France.
I MadelaineService de Pharmacie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), F-75010, Paris, France.
P BriceService d'hémato-Oncologie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), 1, Avenue Claude Vellefaux, 75010, Paris, France.
Catherine ThieblemontService d'hémato-Oncologie, Assistance publique - Hôpitaux de Paris (AP-HP)- Hôpital Saint-Louis (SLS), 1, Avenue Claude Vellefaux, 75010, Paris, France. catherine.thieblemont@aphp.fr.ORCID https://orcid.org/0000-0002-9941-2448
Assistance Publique – Hôpitaux de Paris · FRDélégation Paris 7 · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose methotrexate (HD-MTX) at 3 g/m

Indexed as

AdolescentAdultAmbulatory CareAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBleomycinCentral Nervous SystemChemical and Drug Induced Liver InjuryCyclophosphamideDoxorubicinFemaleHematologic DiseasesHumansInfusions, IntravenousKidney DiseasesKidney Function TestsAntimetabolites, AntineoplasticBleomycinCyclophosphamideDoxorubicinLeucovorinMethotrexatePrednisoneRituximabVincristineVindesineAmbulatoryCNS prophylaxisHigh-dose methotrexateMonitoring(n = 5, < 6)Outpatient

Identifiers

PMID33608849
PMCPMC7960588
OpenAlexW3132912333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.